Sana Biotechnology Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Sana Biotechnology Inc (SANA) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Sana Biotechnology Inc vs Its Competitors
- Scale: Sana Biotechnology Inc ranks #52 of 166 companies by market capitalization in the Biotechnology & Pharmaceuticals industry, holding 0.1% of industry market cap.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
Sana Biotechnology Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Sana Biotechnology Inc | - | - | - | Yes |
| Competitors combined (55) | ||||
| High-Confidence Competitors (28) | ||||
| Similar-Size Competitors (10) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
SANA Stock Performance relative to its Competitors
SANA Stock Performance relative to High-Confidence Competitors
SANA Stock Performance relative to Similar-Size Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Moderna Inc | 282.9% | Outperformed |
| 2 | Immunitybio inc | 282.9% | Outperformed |
| 3 | Century Therapeutics inc | 282.9% | Outperformed |
| 4 | Relay Therapeutics Inc | 282.9% | Outperformed |
| 5 | Replimune Group Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Sana Biotechnology Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Sana Biotechnology Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Sana Biotechnology Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Sana Biotechnology Inc | 682.99 | - |
| Vertex Pharmaceuticals Inc | 130,460.79 | 12,587.20 |
| Moderna Inc | 88,529.13 | 2,228.00 |
| Roivant Sciences Ltd | 25,018.16 | 7.53 |
| Biontech Se | 21,547.56 | 3,243.68 |
| Apogee Therapeutics Inc | 10,190.15 | - |
| SUBTOTAL | 324,469.93 | 21,307.98 |
Sign in to see all competitors of Sana Biotechnology Inc .
Sources: Sana Biotechnology Inc's official press releases and company reports; CSIMarket.com's market research; and the company reports and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Sana Biotechnology Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Sana Biotechnology Inc's Competitors Named by the Company
Competitive relationships identified from Sana Biotechnology Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Vertex Pharmaceuticals Inc. | Company report | 85% |
| Allogene Therapeutics Inc | Company report | 85% |
| Fate Therapeutics Inc | Company report | 85% |
| Gilead Sciences, Inc. | Company report | 85% |
| Legend Biotech Corporation | Company report | 85% |
| Roche Holding AG | Company report | 85% |
| AstraZeneca PLC | Company report | 85% |
| Cabaletta Bio, Inc. | Company report | 85% |
| Kelonia Therapeutics, Inc. | Company report | 85% |
| Aspect Biosystems Ltd. | Company report | 85% |
| Century Therapeutics, Inc. | Company report | 85% |
| Novartis AG | Company report | 85% |
| Docebo Inc | Company report | 85% |
| AbbVie Inc. | Company report | 85% |
| Eli Lilly and Company | Company report | 85% |
| Kyverna Therapeutics, Inc. | Company report | 85% |
| Sab Biotherapeutics Inc | Company report | 85% |
| Bristol-Myers Squibb Company | Company report | 85% |
| CRISPR Therapeutics AG | Company report | 85% |
| Johnson & Johnson | Company report | 85% |
| Umoja Biopharma, Inc. | Company report | 85% |
| Caribou Biosciences, Inc. | Company report | 85% |
| Interius BioTherapeutics, Inc. | Company report | 85% |
| Cargo Therapeutics, Inc. | Company report | 85% |
| Novo Nordisk A/S | Company report | 85% |
| 2seventy bio, Inc. | Company report | 85% |
| Editas Medicine, Inc. | Company report | 85% |
| Orchard Therapeutics plc | Company report | 85% |
| Jasper Therapeutics Inc | Company report | 85% |
| bluebird bio, Inc. | Company report | 85% |
| Sanofi S.A. | Company report | 85% |
| Bayer AG | Company report | 85% |
| Precision BioSciences, Inc. | Company report | 85% |
| Astellas Pharma Inc. | Company report | 85% |
| Aruvant Sciences, Inc. | Company report | 85% |
| Beam Therapeutics Inc. | Company report | 85% |
| ViaCyte Inc. | Company report | 85% |
| Biocardia Inc | Company report | 85% |
| Phoenix Biotech Acquisition Corp | Company report | 85% |
| Senti Biosciences Holdings Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Sana Biotechnology Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from Sana Biotechnology Inc reports (named-competitor disclosures) and corroborating sources. Confidence reflects evidence strength.
Sana Biotechnology Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Vertex Pharmaceuticals Inc | Pharmaceuticals 100.00 % |
| Immunitybio inc | Reportable 100.00 % |
| Novavax inc | Reportable 100.00 % |
| Immunocore Holdings Plc | Reportable 100.00 % |
| Prime Medicine Inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Sana Biotechnology Inc .
Sana Biotechnology Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Sana Biotechnology Inc | 683 | - | -1,491,704 |
| Vertex Pharmaceuticals Inc | 130,461 | 31,079,506 | 10,877,037 |
| Moderna Inc | 88,529 | 474,043 | -670,426 |
| Roivant Sciences Ltd | 25,018 | 10,043 | -552,803 |
| Biontech Se | 21,548 | 415,483 | -164,532 |
| Apogee Therapeutics Inc | 10,190 | - | -1,127,866 |
| PEERS TOTAL | 323,787 | 887,759 | -256,109 |
Sign in to see all peers for Sana Biotechnology Inc .
Sana Biotechnology Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Vertex Pharmaceuticals Inc | United States 61.68 % |
| Krystal Biotech Inc | United States 75.19 % |
| Immunitybio inc | United States 98.99 % |
| Novavax inc | United States 68.88 % |
| 4d Molecular Therapeutics Inc | JP 97.05 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Sana Biotechnology Inc .
Sana Biotechnology Inc's Position in Industry Market Structure
Market-capitalization share and concentration across all 159 companies in Sana Biotechnology Inc's industry classification, broader than the peer set above. Market cap in millions of $.Sana Biotechnology Inc ranks #52 of 159 companies by market capitalization in its industry, holding 0.08 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 1,335, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Amgen Inc | 235,620 | 25.97 % |
| 2 | Gilead Sciences Inc | 194,971 | 21.49 % |
| 3 | Moderna Inc | 88,529 | 9.76 % |
| 4 | Argenx Se | 56,951 | 6.28 % |
| 5 | Revolution Medicines Inc | 1,234 | 5.2% |
| 6 | Biogen Inc | 1,234 | 5.2% |
| 7 | Biontech Se | 1,234 | 5.2% |
| 8 | Exelixis Inc | 1,234 | 5.2% |
| 9 | Mesoblast Limited | 1,234 | 5.2% |
| 10 | Halozyme Therapeutics Inc | 1,234 | 5.2% |
| 52 | Sana Biotechnology Inc | 683 | 0.08 % |
Market cap and industry share for the rest of Sana Biotechnology Inc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-10-20.
Sana Biotechnology Inc's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 47 | 4d Molecular Therapeutics Inc | 901 | 30.23 % |
| 48 | Valneva Se | 900 | -44.82 % |
| 49 | Meiragtx Holdings Plc | 897 | 23.42 % |
| 50 | Solid Biosciences Inc | 859 | 1.70 % |
| 51 | Cullinan Therapeutics Inc | 1,234 | 12.3% |
| 52 | Sana Biotechnology Inc | 683 | -54.08 % |
| 53 | Prime Medicine Inc | 1,234 | 12.3% |
| 54 | Candel Therapeutics Inc | 1,234 | 12.3% |
| 55 | Ginkgo Bioworks Holdings Inc | 1,234 | 12.3% |
| 56 | Aura Biosciences Inc | 1,234 | 12.3% |
| 57 | Surrozen Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Sana Biotechnology Inc's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-10-20. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Sana Biotechnology Inc's Valuation vs Competitive Position
Valuation multiples vs the Biotechnology & Pharmaceuticals industry average (160 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Biotechnology & Pharmaceuticals industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 22.7x | - |
| EV / EBITDA | - | 17.6x | - |
| P/B | 6.0x | 5.0x | +1.0x |
| Return on Equity | -134.49 % | industry aggregate | -131.06 % |
| Return on Invested Capital | -43.28 % | -5.14 % (avg) | -38.14 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Sana Biotechnology Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2021 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | - | - | - | - |
| Operating Margin | - | - | - | - |
| Return on Invested Capital | -16.75 % | -30.71 % | -31.10 % | -45.25 % |
| P/E | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Sana Biotechnology Inc's BCG Growth-Share Matrix
Relative market share (vs Sana Biotechnology Inc's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Sana Biotechnology Inc falls in the Dog quadrant: relative market share of 0.00x vs its largest competitor, in an industry growing revenue 9.0% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution.
Sana Biotechnology Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 1,335 (see Industry Market Structure & Concentration above) |
| Supplier Power | Not covered on this page | See Sana Biotechnology Inc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Sana Biotechnology Inc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Sana Biotechnology Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Sana Biotechnology Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Sana Biotechnology Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 131.1 points below the industry aggregate.
- Underperforming the U.S.A. 500 over the trailing 12 months.
- Low relative market share vs the industry leader (0.00x).
- Piotroski F-Score of 2 or below, the standard financial-distress signal.
Opportunities
- A meaningful share of tracked competitors (51.90 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Sana Biotechnology Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Sana Biotechnology Inc | 0.97 | 1.83 | - |
| Vertex Pharmaceuticals Inc | 1.34 | 2.85 | - |
| Moderna Inc | 0.86 | 2.88 | 0.07 |
| Roivant Sciences Ltd | 12.24 | 22.90 | - |
| Biontech Se | 3.58 | 7.54 | - |
| Apogee Therapeutics Inc | 6.02 | 25.28 | - |
Sign in to see all peers for Sana Biotechnology Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Sana Biotechnology Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Sana Biotechnology Inc | Q2 2026 | - | - |
| Vertex Pharmaceuticals Inc | Q2 2026 | +12.5 % | +6.5 % |
| Moderna Inc | Q2 2026 | +2.1 % | - |
| Roivant Sciences Ltd | Q2 2026 | -33.5 % | - |
| Biontech Se | Q4 2025 | +9.0 % | - |
| Apogee Therapeutics Inc | Q2 2026 | - | - |
| PEERS TOTAL | +13.2 % | - |
Sign in to see all peers for Sana Biotechnology Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Sana Biotechnology Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Sana Biotechnology Inc | Q2 2026 | -4.5 % | - |
| Vertex Pharmaceuticals Inc | Q2 2026 | +20.0 % | -23.0 % |
| Moderna Inc | Q2 2026 | -21.8 % | +1,133.3 % |
| Roivant Sciences Ltd | Q2 2026 | - | -89.6 % |
| Biontech Se | Q4 2025 | +23.9 % | -36.1 % |
| Apogee Therapeutics Inc | Q2 2026 | - | -99.2 % |
Sign in to see all peers for Sana Biotechnology Inc .
Sana Biotechnology Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Sana Biotechnology Inc | - | - | - |
| Vertex Pharmaceuticals Inc | 16.88% | 19.97% | 23.31% |
| Moderna Inc | - | - | - |
| Roivant Sciences Ltd | - | - | - |
| Biontech Se | - | - | - |
| Apogee Therapeutics Inc | - | - | - |
Sign in to see all peers for Sana Biotechnology Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Sana Biotechnology Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Sana Biotechnology Inc | - | - |
| Vertex Pharmaceuticals Inc | 29.81 | 10.36 |
| Moderna Inc | - | 39.73 |
| Roivant Sciences Ltd | - | 3,321.58 |
| Biontech Se | - | 6.64 |
| Apogee Therapeutics Inc | - | - |
| PEERS AVERAGE | - | 15.23 |
Sign in to see all peers for Sana Biotechnology Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.